PG-TXL: Phase I/II

Preliminary results from 2 U.S. trials of PG-TXL showed that the product was well tolerated when given alone or in combination with cisplatin. Results of an open-label Phase I/II trial of PG-TXL as monotherapy in 29 patients with ovarian or peritoneal cancer showed that of 9 currently evaluable patients there were 2 partial responders and 2 patients with stable disease. ...